Tag: TSXV:BCT

January 5, 2021

Biotech Outlook 2021: IPO Craze to Continue Amid COVID-19 Recovery

After an up-and-down year for the market, what’s in store for the biotech space and its investors in 2021?
August 17, 2020

BriaCell Presents Clinical and Scientific Findings at the Annual Symposium of Society of Surgical Oncology 2020

Preliminary safety and efficacy data are being presented today from the clinical trials of Bria-IMT™ in combination with immune checkpoint...
February 28, 2019

Innovation in Breast Cancer Treatment: Combination and Off-the-Shelf Personalized Immunotherapies

Advancements for breast cancer patients are being led by breast cancer combination therapy innovations, and off-the-shelf personalized immunotherapy
February 3, 2019

Checkpoint Inhibitors Driving the Immunotherapy Market

The multibillion-dollar immunotherapy market is expected to experience further growth on advancements in checkpoint inhibitor biotechnology.
December 19, 2018

Biotech Outlook 2019: Will the Pressure Continue?

With 2018 coming to an end, what's the biotech outlook? Next year will bring new investing opportunities for those in...
October 7, 2018

BriaCell CEO: Building Offerings for the $30-billion Immunotherapy Market

BriaCell CEO Dr. William Williams discusses his company’s success in developing immunotherapies targeting breast and other cancers.
September 26, 2018

BriaCell Announces Positive Phase IIa Proof of Concept Data in Advanced Breast Cancer; Initiates Combination Study

BriaCell Therapeutics Corp. (“BriaCell”, the “Company”) (TSXV:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is...